Corvus Pharmaceuticals
CRVS
50 hedge funds and large institutions have $63.2M invested in Corvus Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
8.56% more ownership
Funds ownership: 53.24% → 61.8% (+8.6%)
2% more funds holding
Funds holding: 49 → 50 (+1)
1% more capital invested
Capital invested by funds: $62.8M → $63.2M (+$396K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
60% less call options, than puts
Call options by funds: $104K | Put options by funds: $261K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$9.85M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$1.24M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$300K |
| 4 |
BlackRock
New York
|
+$147K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$115K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$1.04M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$742K |
| 3 |
LCM
Laurion Capital Management
New York
|
-$614K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$294K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$153K |
CRVS Hedge Fund Activity: Q2 2021 in Review
50 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q2 2021, worth a combined $63.2M — up 0.63% from $62.8M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CRVS positions and 3 closed out — a net gain of 1 holder — while 13 added to existing stakes and 17 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $9.85M. The largest seller was Bank Julius Baer & Co, exiting entirely with an estimated $1.04M sold.
- 50 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q2 2021, up from 49 in Q1 2021.
- Funds reported $63.2M of Corvus Pharmaceuticals stock for Q2 2021, up 0.63% quarter-over-quarter.
- 4 funds opened new Corvus Pharmaceuticals positions in Q2 2021 and 3 closed out, a net change of +1 holder.
- The largest Corvus Pharmaceuticals buyer in Q2 2021 was EcoR1 Capital, an estimated $9.85M added.
- The largest Corvus Pharmaceuticals seller in Q2 2021 was Bank Julius Baer & Co, an estimated $1.04M sold.
Based on aggregated 13F filings for Q2 2021.